# Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE

> **NCT04720768** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Peter MacCallum Cancer Centre, Australia** · enrollment: 78 (estimated)

## Conditions studied

- Melanoma
- Metastasis

## Interventions

- **DRUG:** Binimetinib
- **DRUG:** Encorafenib
- **DRUG:** Palbociclib

## Key facts

- **NCT ID:** NCT04720768
- **Lead sponsor:** Peter MacCallum Cancer Centre, Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-04
- **Primary completion:** 2024-12-04
- **Final completion:** 2024-12-04
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2024-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04720768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04720768, "Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04720768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*